BioCryst Pharmaceuticals, Inc.
NASDAQBioCryst Pharmaceuticals is sending conflicting signals. Short sellers are rebuilding aggressively. Options traders are betting the other way at a year-low intensity. The gap between those two camps has widened sharply this week. Short interest stands at 20.4% of free float — up 15.2% in a single week. That is one of the heavier short loads in…
BCRX cost to borrow surges to 4.38% — up 111% over one week, marking highest level since April peak.
BioCryst Pharmaceuticals is sending conflicting signals. Short sellers are rebuilding aggressively. Options traders are betting the other way at a year-low intensity. The gap between those two camps has widened sharply…
BioCryst Pharmaceuticals heads into the final week of June with a striking divergence: short interest is climbing to a one-month high while options traders have swung to their most bullish posture in at least a…
Snapshot as of 6 Aug 2026
BioCryst Pharmaceuticals enters late May with short sellers holding a firm grip — and the cost to maintain that position just jumped sharply. Short interest is running near 18% of the free float, a level that has…
BioCryst Pharmaceuticals heads into the post-earnings period with a striking bifurcation: short interest has jumped back toward cycle highs while borrowing costs have crashed to their lowest levels of the year — a…
BioCryst Pharmaceuticals heads into its May 4 Q1 earnings call with short sellers rebuilding positions at pace — and options traders turning more defensive than at any point in recent memory. The week's most striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCRX — free to start on ORTEX.
Sign up for free →Open BCRX on ORTEX